69 related articles for article (PubMed ID: 8389321)
21. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
22. [Detection of the PML/RAR alpha rearrangement in acute promyelocytic leukemia using a reverse PCR method].
Barragán E; Bonanad S; López JA; Martín G; Martínez J; Sanz GF; Gomis F; Pérez ML; Senent ML; Larrea L; Bolufer P; Sanz MA
Sangre (Barc); 1996 Jun; 41(3):189-94. PubMed ID: 8755206
[TBL] [Abstract][Full Text] [Related]
23. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.
Muindi J; Frankel SR; Miller WH; Jakubowski A; Scheinberg DA; Young CW; Dmitrovsky E; Warrell RP
Blood; 1992 Jan; 79(2):299-303. PubMed ID: 1309668
[TBL] [Abstract][Full Text] [Related]
24. The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias.
Chomienne C; Ballerini P; Balitrand N; Huang ME; Krawice I; Castaigne S; Fenaux P; Tiollais P; Dejean A; Degos L; de The H
Leukemia; 1990 Dec; 4(12):802-7. PubMed ID: 2173802
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells.
Chelbi-Alix MK; Pelicano L
Leukemia; 1999 Aug; 13(8):1167-74. PubMed ID: 10450744
[TBL] [Abstract][Full Text] [Related]
26. Use of trans-retinoic acid in the treatment of acute promyelocytic leukemia.
Dulaney AM; Murgatroyd RJ
Ann Pharmacother; 1993 Feb; 27(2):211-4. PubMed ID: 8439701
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.
Ablain J; de Thé H
Int J Cancer; 2014 Nov; 135(10):2262-72. PubMed ID: 25130873
[TBL] [Abstract][Full Text] [Related]
28. A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (review).
Kizaki M; Fukuchi Y; Ikeda Y
Int J Mol Med; 1999 Oct; 4(4):359-64. PubMed ID: 10493975
[TBL] [Abstract][Full Text] [Related]
29. Retinoid resistance in leukemic cells.
Kizaki M; Ueno H; Matsushita H; Takayama N; Muto A; Awaya N; Ikeda Y
Leuk Lymphoma; 1997 May; 25(5-6):427-34. PubMed ID: 9250812
[TBL] [Abstract][Full Text] [Related]
30. RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells.
Youn H; Lee HK; Sohn HR; Park UH; Kim EJ; Youn B; Um SJ
Oncogene; 2018 Jan; 37(3):352-362. PubMed ID: 28945224
[TBL] [Abstract][Full Text] [Related]
31. Trans-retinoic acid and related differentiation agents.
Parkinson DR; Smith MA; Cheson BD; Stevenson HC; Friedman MA
Semin Oncol; 1992 Dec; 19(6):734-41. PubMed ID: 1462170
[TBL] [Abstract][Full Text] [Related]
32. Applications for retinoids in cancer therapy.
Warrell RP
Semin Hematol; 1994 Oct; 31(4 Suppl 5):1-13. PubMed ID: 7831579
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy: will it deliver for RA?
Gabay C
Drug Discov Today; 2001 Apr; 6(7):343-344. PubMed ID: 11267919
[No Abstract] [Full Text] [Related]
34. Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.
Gillis JC; Goa KL
Drugs; 1995 Nov; 50(5):897-923. PubMed ID: 8586032
[TBL] [Abstract][Full Text] [Related]
35. Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia.
Miller WH; Dmitrovsky E
Important Adv Oncol; 1993; ():81-90. PubMed ID: 8389321
[TBL] [Abstract][Full Text] [Related]
36. Retinoic acid and its rearranged receptor in the etiology and treatment of acute promyelocytic leukemia.
Frankel SR; Miller WH; Dmitrovsky E
Oncology (Williston Park); 1992 Aug; 6(8):74-78, 83; discussion 84, 87-8. PubMed ID: 1323988
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic reversion in acute promyelocytic leukemia.
Degos L
Nouv Rev Fr Hematol (1978); 1991; 33(6):511-5. PubMed ID: 1667950
[TBL] [Abstract][Full Text] [Related]
38. All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy.
Degos L
Int J Cell Cloning; 1992 Mar; 10(2):63-9. PubMed ID: 1312109
[TBL] [Abstract][Full Text] [Related]
39. Retinoic acid in acute promyelocytic leukemia: the promise and the paradox.
Clarkson B
Cancer Cells; 1991 Jun; 3(6):211-20. PubMed ID: 1911035
[TBL] [Abstract][Full Text] [Related]
40. Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells.
Zhou DC; Hallam SJ; Lee SJ; Klein RS; Wiernik PH; Tallman MS; Gallagher RE
Cancer Res; 1998 Dec; 58(24):5770-6. PubMed ID: 9865735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
